Indicated for type 2 diabetes mellitus to manage blood glucose and support insulin release.
Mechanism of Action
Glimepiride stimulates insulin secretion from pancreatic beta cells by binding to and closing ATP-dependent potassium channels. This depolarization opens calcium channels, triggering the release of stored insulin into the bloodstream.
Route of Administration
Oral
Onset Time
1 hour
Duration
24 hours
Contraindications
Type 1 diabetes, Diabetic ketoacidosis, Hypersensitivity to glimepiride, Hypersensitivity to sulfonamides
Severe Adverse Events
Severe hypoglycemia, Cholestatic jaundice, Hemolytic anemia — requires immediate medical attention
Information related to Glimepiride is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
